journal article·2002-07

Targeting of Polyelectrolyte RNA Complexes to Cell Surface Integrins as an Efficient Cytoplasmic Transfection Mechanism

Alan L. Parker, Leonard W. Seymour

Publisher page

Abstract

This is the first demonstration of receptor-mediated delivery of mRNA and establishes a new approach to gene therapy. Messenger RNA (mRNA) provides a promising alternative to plasmid DNA as a genetic material for delivery in non-viral gene therapy strategies. Since it does not require access to the nucleus and is less dependent on the cell cycle for expression, mRNA delivered using cationic lipids or short cationic polymers can be effectively translated within target cells. In this study, mRNA formed discrete nanoparticles following self assembly with a range of cationic polymers. Based on transfection activities, the low molecular weight polycations were more efficient than high molecular weight, while protamine and polyethylenimine were far more efficient than poly(L-lysine). Receptor-mediated delivery of mRNA was demonstrated using the synthetic polyamino acid (K) 16 GACDCRGDCFCA designed to promote cell entry following interaction with cell surface α υ integrins. RGD-bearing mRNA complexes showed very high levels of expression, reaching over 60% transduction of B16F10 cells.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TA United Kingdom

Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE.

References (19)

Show source-provided references
1. 10.1016/S0169-409X(01)00213-710.1016/S0169-409X(01)00213-7 ↗
2. Liu, F. · J. ControlRelease · 2002 · 78 · 259
3. 10.1006/mthe.2001.047210.1006/mthe.2001.0472 ↗
4. 10.1074/jbc.M10833120010.1074/jbc.M108331200 ↗
5. 10.1074/jbc.273.13.750710.1074/jbc.273.13.7507 ↗
6. 10.1093/nar/29.18.388210.1093/nar/29.18.3882 ↗
7. 10.1038/sj.gt.330093010.1038/sj.gt.3300930 ↗
8. Lu, D. · Cancer Gene Ther. · 1994 · 1 · 245
9. 10.1021/bi960201910.1021/bi9602019 ↗
10. 10.1007/s00432000020110.1007/s004320000201 ↗
11. Heiser, A. · Cancer Res. · 2001 · 61 · 3388
12. Rains, N. · Hepatogastroenterology · 2001 · 48 · 347
13. 10.1073/pnas.86.16.607710.1073/pnas.86.16.6077 ↗
14. 10.1038/sj.gt.330109510.1038/sj.gt.3301095 ↗
15. 10.1038/sj.gt.330051310.1038/sj.gt.3300513 ↗
16. Wolfert, M.A. · Gene Ther. · 1996 · 3 · 269
17. 10.1073/pnas.92.16.729710.1073/pnas.92.16.7297 ↗
18. Boussif, O. · Gene Ther. · 1996 · 3 · 1074
19. 10.1006/mthe.2001.027910.1006/mthe.2001.0279 ↗